Skip to main content
HERAMED LIMITED logo

HERAMED LIMITED — Investor Relations & Filings

Ticker · HMD ISIN · AU0000028367 LEI · 875500WOB41XBFTTJ477 ASX Manufacturing
Open in API
Filings indexed 524 across all filing types
Latest filing 2019-02-13 Capital/Financing Update
Country AU Australia
Listing ASX HMD

About HERAMED LIMITED

https://hera-med.com/

HeraMED Limited is a medical technology company specializing in the development and commercialization of digital health solutions for maternity care. The company focuses on providing remote monitoring tools that bridge the gap between expectant mothers and healthcare providers. Its flagship product, HeraBEAT, is a medical-grade, smartphone-based fetal heart rate monitor designed for home use, allowing for accurate and reliable monitoring of fetal well-being. This hardware is integrated into the HeraCARE platform, a comprehensive digital maternity care solution that enables remote data management, personalized care plans, and seamless communication between patients and clinicians. By leveraging cloud-based technology and advanced sensors, the company aims to enhance prenatal care, improve clinical outcomes, and offer peace of mind through continuous, data-driven insights throughout the pregnancy journey.

Recent filings

Filing Released Lang Actions
Major Brazilian Health Care Group Places Initial Pilot Order 2 pages 182.6KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 14 February 2019, describing a commercial order and partnership between HeraMED and a major Brazilian healthcare provider, Hapvida. It details the initial pilot order for HeraMED's products and services, including software and subscription fees, and mentions regulatory approval (ANVISA). The content focuses on business development, product orders, and strategic partnerships rather than financial results, management changes, or regulatory filings. There is no indication of financial statements, earnings data, or report attachments. The document is a corporate announcement about a capital or business development event related to financing or revenue generation through SaaS and cloud services. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2019-02-13 English
December Quarterly Activity Report & Appendix 4C 7 pages 331.5KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'December Quarterly Activity Report' and is dated 31 January 2019, covering the quarter ended 31 December 2018. It includes detailed operational updates, cash flow statements, and financial data for the quarter, including an Appendix 4C quarterly report which is a standard Australian Securities Exchange (ASX) quarterly cash flow report. The document contains substantive financial data and analysis for a period shorter than a full fiscal year (a quarter). It is not an announcement of a report publication but the report itself. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q4 2018
2019-01-30 English
Australian Distribution Agreement for 9000 HeraBEAT Units 2 pages 140.3KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 14 January 2019 about a binding exclusive distribution agreement signed between HeraMED Limited and Dale Group International. It details the terms of the distribution deal, including minimum unit commitments and marketing collaboration. There is no financial report, earnings data, or regulatory filing referenced. The document is a corporate announcement about a capital/financing related business update (distribution deal), not a report or regulatory filing. The length is 3245 characters, which is short and typical for an announcement. Therefore, the document fits best under Capital/Financing Update (CAP).
2019-01-13 English
Becoming a substantial holder - Holley Pharmaceutical Group 2 pages 277.9KB
Major Shareholding Notification Classification · 100% confidence The document is titled 'Form 603' and references the Corporations Act 2001 Section 671B, which pertains to notices of initial substantial holders. It details the substantial holder's name, voting power, relevant interests, registered holders, and consideration paid. This is a notification of a change in significant share ownership levels, specifically the initial substantial holder notice. There is no financial data, earnings, management discussion, or other report content. The document is a regulatory filing related to major shareholding notification. According to the filing definitions, this fits best under 'Major Shareholding Notification (MRQ)'. The document length is 4602 characters, which is consistent with a detailed notification rather than a brief announcement or a full report.
2018-12-18 English
December Investor Presentation 23 pages 3.2MB
Regulatory Filings
2018-12-18 English
HeraMED Completes Over-Subscribed $6 Million IPO 2 pages 162.2KB
Capital/Financing Update Classification · 95% confidence The document is a press release dated 12 December 2018 announcing HeraMED's successful completion of an over-subscribed $6 million Initial Public Offering (IPO) on the ASX. It details the use of funds, regulatory approvals, partnerships, and upcoming product launches. The content focuses on capital raising and financing activities rather than financial results, management changes, or regulatory filings. The document length is 4110 characters, which is relatively short and typical for an announcement rather than a full report. There is no indication that this is a full financial report or an earnings release. The primary subject is the completion of a capital raising event (IPO). Therefore, the appropriate classification is Capital/Financing Update (CAP).
2018-12-11 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.